

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Hydrocortisone aceponate Ecuphar 0.584 mg/ml cutaneous spray solution for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of solution contains:

Active substance:

Hydrocortisone aceponate 0.584 mg,
Equivalent to 0.460 mg of hydrocortisone

Excipients:

Qualitative composition of excipients and other constituents

Propylene glycol methyl ether

Clear colourless to slightly yellow solution.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
For alleviation of clinical signs associated with atopic dermatitis in dogs.

3.3 Contraindications

Do not use on cutaneous ulcers.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Clinical signs of atopic dermatitis such as pruritus and skin inflammation are not specific for this disease and therefore other causes of dermatitis such as ectoparasitic infestations and infections which cause dermatological signs should be ruled out before treatment is started, and underlying causes should be investigated.

In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.

In the absence of specific information, the use in animals suffering from Cushing's syndrome shall be based on the risk-benefit assessment.

Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.

Total body surface treated should not exceed approximately 1/3 of the dog's surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs. See also section 3.10. Otherwise, use only according to the risk-benefit assessment of the responsible veterinary surgeon and subject the dog to regular clinical evaluations as further described in section 3.9.

Care should be taken to avoid spraying into the eyes of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The active substance is potentially pharmacologically active at high doses of exposure.

The formulation may cause eye irritation following accidental ocular contact.

The formulation is flammable.

Wash hands after use. Avoid contact with eyes.

To avoid skin contact, recently treated animals should not be handled until the application site is dry.

To avoid inhalation of the product, apply the spray in a well-ventilated area.

Do not spray on naked flame or any incandescent material.

Do not smoke while handling the veterinary medicinal product.

Replace the bottle in the outer carton and in a safe place out of the sight and the reach of children immediately after use.

In case of accidental skin contact, avoid hand-to-mouth contact and wash the exposed area immediately with water.

In case of accidental eye contact, rinse with abundant quantities of water.

If eye irritation persists, seek medical advice.

In case of accidental ingestion, especially by children, seek medical advice immediately and show the leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

Other precautions:

The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

3.6 Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Application site erythema*, application site pruritus*
---	--

* transient

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing

authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs. Use only accordingly to the risk-benefit assessment by the responsible veterinarian.

3.8 Interaction with other medicinal products and other forms of interaction

No data available.

In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.

3.9 Administration routes and dosage

Cutaneous use.

Before administration, screw the pump spray on the bottle.

The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.

The recommended dosage is 1.52 mcg of hydrocortisone aceponate/cm² of affected skin per day. This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm.

- For treatment of inflammatory and pruritic dermatoses, repeat the treatment daily for 7 consecutive days.
In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.
If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.
- For alleviation of clinical signs associated with atopic dermatitis, repeat the treatment daily for at least 14 and up to 28 consecutive days.
An intermediary control by the veterinarian at day 14 should be made to decide if further treatment is needed. The dog should be re-evaluated regularly with regard to HPA suppression or skin atrophy, both being possibly asymptomatic.
Any prolonged use of this product, to control atopy, should be at the benefit risk assessment of the responsible veterinary surgeon. It should take place after a re-evaluation of the diagnosis and also a consideration of the multi-modal treatment plan in the individual animal.

Presented as a volatile spray, this veterinary medicinal product does not require any massage.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Tolerance studies of multiple doses were assessed over a period of 14 days in healthy dogs using 3 and 5 times the recommended dosage corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs (1/3 of the dog's body surface area). These resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.

In 12 dogs suffering from atopic dermatitis, after topical application once a day at the recommended therapeutic dosage for 28 to 70 (n=2) consecutive days, no noticeable effect on the systemic cortisol level was observed.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QD07AC16

4.2 Pharmacodynamics

The veterinary medicinal product contains the active substance hydrocortisone aceponate. Hydrocortisone aceponate is a dermocorticoid with a potent intrinsic glucocorticoid activity which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions observed in case of inflammatory and pruritic dermatosis. In case of atopic dermatitis, improvement will be slower.

4.3 Pharmacokinetics

Hydrocortisone aceponate belongs to the diesters class of the glucocorticosteroids. The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a low plasma availability. Hydrocortisone aceponate thus accumulates in the dog's skin allowing local efficacy at low dosage. The diesters are transformed inside the skin structures. This transformation is responsible for the potency of the therapeutic class. In laboratory animals, hydrocortisone aceponate is eliminated the same way as hydrocortisone (other name for endogenous cortisol) through urine and faeces. Topical application of diesters results in high therapeutic index: high local activity with reduced systemic secondary effects.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 6 months.

5.3 Special precautions for storage

Do not store above 25 °C.

5.4 Nature and composition of immediate packaging

White polyethylene terephthalate (PET) bottle closed with a white polypropylene screw cap with bore seal and supplied with a spray pump.

Cardboard box containing 1 bottle of 76 ml.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Ecuphar NV

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/18/230/001

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 27/08/2018

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARDBOARD BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Hydrocortisone aceponate Ecuphar 0.584 mg/ml cutaneous spray solution

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains 0.584 mg of hydrocortisone aceponate.

3. PACKAGE SIZE

76 ml

4. TARGET SPECIES

Dogs.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Cutaneous use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened use within 6 months.

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER



14. MARKETING AUTHORISATION NUMBERS
--

EU/2/18/230/001

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

BOTTLE (PET)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Hydrocortisone aceponate Ecuphar 0.584 mg/ml cutaneous spray solution

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains 0.584 mg of hydrocortisone aceponate.

3. TARGET SPECIES

Dogs.

4. ROUTES OF ADMINISTRATION

Cutaneous use.

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

6. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use within 6 months.

7. SPECIAL STORAGE PRECAUTIONS

Do not store above 25 °C.

8. NAME OF THE MARKETING AUTHORISATION HOLDER



9. BATCH NUMBER

Lot {number}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Hydrocortisone aceponate Ecuphar 0.584 mg/ml cutaneous spray solution for dogs

2. Composition

Each ml of solution contains:

Active substance:

Hydrocortisone aceponate 0.584 mg,
Equivalent to 0.460 mg of hydrocortisone

Clear colourless to slightly yellow solution.

3. Target species

Dogs.

4. Indications for use

For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
For alleviation of clinical signs associated with atopic dermatitis in dogs.

5. Contraindications

Do not use on cutaneous ulcers.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:

Clinical signs of atopic dermatitis such as pruritus and skin inflammation are not specific for this disease and therefore other causes of dermatitis such as ectoparasitic infestations and infections which cause dermatological signs should be ruled out before treatment is started, and underlying causes should be investigated.

In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.

In the absence of specific information, the use in animals suffering from Cushing's syndrome shall be based on the risk-benefit assessment.

Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.

Total body surface treated should not exceed approximately 1/3 of the dog's surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs. See also section 'Overdose'. Otherwise, use only according to the risk-benefit

assessment of the responsible veterinary surgeon and subject the dog to regular clinical evaluations as further described in section 'Dosage for each species, route(s) and method of administration'.

Care should be taken to avoid spraying into the eyes of the animal.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The active substance is potentially pharmacologically active at high doses of exposure.

The formulation may cause eye irritation following accidental ocular contact.

The formulation is flammable.

Wash hands after use. Avoid contact with eyes.

To avoid skin contact, recently treated animals should not be handled until the application site is dry.

To avoid inhalation of the product, apply the spray in a well-ventilated area.

Do not spray on naked flame or any incandescent material.

Do not smoke while handling the veterinary medicinal product.

Replace the bottle in the outer carton and in a safe place out of the sight and the reach of children immediately after use.

In case of accidental skin contact, avoid hand-to-mouth contact and wash the exposed area immediately with water.

In case of accidental eye contact, rinse with abundant quantities of water.

If eye irritation persists, seek medical advice.

In case of accidental ingestion, especially by children, seek medical advice immediately and show the leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

Other precautions:

The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs. Use only accordingly to the risk-benefit assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.

Overdose:

Tolerance studies of multiple doses were assessed over a period of 14 days in healthy dogs using 3 and 5 times the recommended dosage corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs (1/3 of the dog's body surface area). These resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.

In 12 dogs suffering from atopic dermatitis, after topical application once a day at the recommended therapeutic dosage for 28 to 70 (n=2) consecutive days, no noticeable effect on the systemic cortisol level was observed.

Major incompatibilities:

None known.

7. Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Application site erythema (skin redness)*, application site pruritus(itching)*
---	--

* transient

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Cutaneous use.

Before administration, screw the pump spray on the bottle.

The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.

The recommended dosage is 1.52 mcg of hydrocortisone aceponate/cm² of affected skin per day. This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm.

- For treatment of inflammatory and pruritic dermatoses, repeat the treatment daily for 7 consecutive days.
In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.
If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.
- For alleviation of clinical signs associated with atopic dermatitis, repeat the treatment daily for at least 14 and up to 28 consecutive days.
An intermediary control by the veterinarian at day 14 should be made to decide if further treatment is needed. The dog should be re-evaluated regularly with regard to HPA suppression or skin atrophy, both being possibly asymptomatic.
Any prolonged use of this product, to control atopy, should be at the benefit risk assessment of the responsible veterinary surgeon. It should take place after a re-evaluation of the diagnosis and also a consideration of the multi-modal treatment plan in the individual animal.

9. Advice on correct administration

Spray preferably in a well ventilated area. Flammable.

Do not spray on naked flame or any incandescent material. Do not smoke while handling the product. Presented as a volatile spray, this veterinary medicinal product does not require any massage.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 25 °C.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 6 months.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/18/230/001

Cardboard box containing 1 bottle of 76 ml.

15. Date on which the package leaflet was last revised

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder:

Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

Manufacturer responsible for batch release:

Divasa Farmavic SA
Ctra. Sant Hipòlit, km 71
08503 Gurb-Vic, Barcelona
Spain

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tél/Tel: + 32 50314269
info@ecuphar.be

Република България

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Česká republika

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Danmark

Scanvet Animal Health A/S
Kongevej 66
DK-3480 Fredensborg
Tel: +45 48 48 43 17
info@scanvet.dk

Deutschland

Ecuphar GmbH
Brandteichstraße 20
DE-17489 Greifswald
Tel: + 49 3834835840
info@ecuphar.de

Eesti

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Lietuva

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Luxembourg/Luxemburg

Ecuphar SA
Legeweg 157-i
BE-8020 Oostkamp
Tél/Tel: + 32 50314269
info@ecuphar.be

Magyarország

Pannon VetPharma Kft.
Hankóczy Jenő u. 21/A
HU-1022 Budapest
Tel: +36 30 650 0 650
pannonvetpharma@gmail.com

Malta

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Nederland

Ecuphar bv
Verlengde Poolseweg 16
NL-4818 CL Breda
Tel: + 31 880033800
info@ecuphar.nl

Norge

Scanvet Animal Health A/S
Kongevej 66
DK-3480 Fredensborg
Tel: +45 48 48 43 17
info@scanvet.dk

Ελλάδα

Hellafarm Vet S.A.
1st km L.Peanias – Markopoulou
EL-19002 Peania
Tel: +30 210 68 95 188
info@hellafarmvet.gr

España

Ecuphar Veterinaria SLU
C/Cerdanya, 10-12 Planta 6
ES-08173 Sant Cugat del Vallés, Barcelona
Tel: + 34 935955000
info@ecuphar.es

France

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Hrvatska

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Ireland

Duggan Veterinary Supplies Ltd
Unit 9 Thurles Retail Park, Thurles, Co.
Tipperary
IE-E41 E7K7
Tel: +353 504 43169
sales@dugganvet.ie

Ísland

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Italia

Ecuphar Italia S.r.l.
Viale Francesco Restelli, 3/7
IT-20124 Milano
Tel: + 39 0282950604
info@ecuphar.it

Österreich

Ecuphar GmbH
Brandteichstraße 20
DE-17489 Greifswald
Tel: + 49 3834835840
info@ecuphar.de

Polska

ScanVet Poland Sp. z o.o.
ul. Kiszowska 9
PL - 62-200 Gniezno
Tel: +48 614264920
pharmacovigilance@scanvet.pl

Portugal

Belpar Lda
Sintra Business Park 7, Edifício 1, Escritório 2K
Zona Industrial de Abrunheira
PT-2710-089 Sintra
Tel: + 351 308808321
info@ecuphar.pt

România

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Slovenija

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Slovenská republika

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Suomi/Finland

Vetcare Oy
PL/PB 99
FI-24101 Salo
+358201443360
vetcare@vetcare.fi

Κύπρος

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Latvija

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be

Sverige

Nordvacc Läkemedel AB
Västertorpsvägen 135
Postal adress: Box 112
SE-129 22 Hägersten
Tel: +46 8-120 10 650
vet@nordvacc.se

United Kingdom (Northern Ireland)

Ecuphar NV/SA
Legeweg 157-i
BE-8020 Oostkamp
Tel: + 32 50314269
info@ecuphar.be